March 2026
Mystical experience
What March 2026's 4 new studies found, synthesized from the papers below. All Mystical experience research →
The synthesis
Synthesized from 4 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for Mystical experience, mystical-type experience, ego dissolution, unitive experience, peak experience, then ranked by relevance.
Research in March 2026 found that mystical experiences induced by esketamine in treatment-resistant depression patients are common (58% of patients) and associated with greater antidepressant improvement, while a scoping review across psychedelic therapy trials confirmed that mystical-type experiences are linked to reduced anxiety and depression in both life-threatening disease and depressive populations. A conceptual model proposed that ego dissolution reduces death anxiety and improves impulse regulation, and an LSD neuroimaging study showed that ego dissolution is specifically linked to frequency-selective decoupling of the default-mode network. Caveats include the observational design of the esketamine study, the conceptual nature of the psychological model, and the need for further empirical validation across populations.
Confidence in the evidence
Moderate- Two empirical studies (one observational with 45 patients, one scoping review of 13 trials with 410 participants) provide converging evidence for the therapeutic relevance of mystical experiences.
- The esketamine study is observational and open-label, limiting causal inference, while the scoping review synthesizes clinical trials but includes heterogeneous populations.
- The conceptual model and neuroimaging study offer mechanistic insights but are not direct tests of therapeutic outcomes.
- No large-scale, blinded, randomized controlled trials specifically testing mystical experience as a mediator were published in this month.
How we rate confidence
Confidence reflects the strength of the underlying evidence, not whether the result is favorable. It weighs the number and size of studies, their design (randomized trials count for more than observational or single-case work), how consistently they point the same way, and their risk of bias.
Tiers run from Insufficient to High. High is rare in this field: small, early, or open-label studies land lower even when their direction is encouraging.
Evidence by study
Direction is each study's finding relative to your question: Supports, Opposes, No effect, Mixed, or Unclear.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Mystical Experience Induced by Esketamine Treatment: A Real-World Observational Study 2026 | observational | 45 | Supports | Mystical experiences occurred in 58% of patients, and higher MEQ scores were associated with greater improvement in depression scores, while dissociative effects were not. |
| Ego Dissolution, Death Anxiety, and Impulse Regulation: A Conceptual Psychological Model of Contemplative Transformation 2026 | theoretical | Supports | The conceptual model proposes that ego dissolution reduces death anxiety and improves impulse regulation, mediating psychological benefits of contemplative practices. | |
| LSD Relaxes Structural Constraints on Brain Dynamics and Default Mode Decoupling Tracks Ego Dissolution 2026 | observational | Supports | LSD-induced ego dissolution was predicted by gamma-band decoupling within default-mode network regions, indicating frequency-selective neural reorganization. | |
| A scoping review of mystical-type experiences and mood symptom outcomes in psychedelic therapy clinical trials: comparing life-threatening disease and depressive populations 2026 | review | 410 | Supports | The scoping review found that mystical-type experiences are consistently associated with reduced anxiety and depression across both life-threatening disease and depressive populations. |
Mystical experiences occurred in 58% of patients, and higher MEQ scores were associated with greater improvement in depression scores, while dissociative effects were not.
observational Sample size: 45
The conceptual model proposes that ego dissolution reduces death anxiety and improves impulse regulation, mediating psychological benefits of contemplative practices.
theoretical
LSD-induced ego dissolution was predicted by gamma-band decoupling within default-mode network regions, indicating frequency-selective neural reorganization.
observational
The scoping review found that mystical-type experiences are consistently associated with reduced anxiety and depression across both life-threatening disease and depressive populations.
review Sample size: 410
Points of agreement
- Mystical-type experiences are consistently associated with positive mood and therapeutic outcomes across different psychedelic agents (esketamine, LSD) and clinical populations.
- Ego dissolution or mystical experience is linked to neural changes in the default-mode network.
- The therapeutic benefits of mystical experiences appear to extend beyond simple dissociative effects.
Conflicts
- The esketamine study found that dissociative effects were not related to antidepressant improvement, while the conceptual model emphasizes ego dissolution as a key mechanism, suggesting different subjective effects may have distinct roles.
- The scoping review notes potential differences between life-threatening disease and depressive populations, but the evidence is not yet conclusive.
Gaps
- Durability of mystical experience-related therapeutic gains is not addressed in these studies.
- Blinding and placebo control are lacking in the esketamine observational study.
- Direct comparisons between different clinical populations (e.g., life-threatening disease vs. depression) remain understudied.
- The conceptual model requires empirical validation in controlled trials.
- Dose-response relationships and optimal frequency of mystical experiences are not established.